CA
NZ
UK
AU
IND
US
…
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Delcath Systems, Inc. develops an isolated hepatic perfusion system to deliver high‑dose chemotherapy directly to the liver for treatment of primary and metastatic liver tumors. Long‑term growth may be supported by clinical trial results, regulatory approvals, commercial adoption in interventional oncology and partnerships for broader market access. Investors may find the company attractive for its focused, device‑based approach to a niche oncology indication that could benefit from alternatives to systemic chemotherapy.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 3.51M | -26.39M | -47.68M | -36.51M | -25.65M |
| Net income | 2.70M | -26.39M | -47.68M | -39.16M | -26.76M |
| Selling general administrative | 43.53M | 29.55M | 18.97M | 17.30M | 13.64M |
| Gross profit | 73.43M | 31.02M | 1.43M | 2.03M | 2.88M |
| Reconciled depreciation | 0.35M | 0.23M | 0.12M | 0.13M | 0.15M |
| Ebit | 3.51M | -12.41M | -38.18M | -33.85M | -24.53M |
| Ebitda | 3.86M | -12.18M | -37.78M | -33.69M | -24.46M |
| Depreciation and amortization | 0.35M | 0.23M | 0.40M | 0.16M | 0.07M |
| Non operating income net other | - | - | - | 0.03M | - |
| Operating income | 0.66M | -12.41M | -38.18M | -33.85M | -24.53M |
| Other operating expenses | 84.57M | 49.62M | 40.25M | 36.57M | 28.09M |
| Interest expense | - | 0.12M | 1.44M | 2.69M | 1.19M |
| Tax provision | 0.81M | 0.00M | - | - | - |
| Net interest income | 2.92M | 0.12M | -2.10M | -2.69M | -1.19M |
| Income tax expense | 0.81M | - | -0.04M | 2.65M | 1.11M |
| Total revenue | 85.23M | 37.20M | 2.06M | 2.72M | 3.56M |
| Total operating expenses | 72.77M | 43.43M | 39.61M | 35.89M | 27.41M |
| Cost of revenue | 11.80M | 6.19M | 0.64M | 0.69M | 0.67M |
| Total other income expense net | 2.85M | -13.98M | -9.50M | -2.65M | -1.12M |
| Net income from continuing ops | 2.70M | -26.39M | -45.01M | -36.51M | -25.65M |
| Net income applicable to common shares | - | - | - | -36.51M | -25.65M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 123.63M | 76.59M | 38.61M | 17.86M | 33.12M |
| Other current assets | 6.50M | 2.53M | 0.94M | 0.10M | 2.74M |
| Total liab | 12.41M | 7.84M | 22.84M | 23.72M | 21.17M |
| Total stockholder equity | 111.22M | 68.75M | 15.78M | -5.86M | 11.95M |
| Other current liab | 8.19M | 5.08M | 5.25M | 4.68M | 4.11M |
| Common stock | 0.35M | 0.33M | 0.23M | 0.10M | 0.08M |
| Capital stock | 0.35M | 0.33M | 0.23M | 0.10M | 0.08M |
| Retained earnings | -528.85M | -531.55M | -505.16M | -457.48M | -420.98M |
| Other liab | - | - | - | 1.06M | - |
| Other assets | - | - | 0.00M | - | - |
| Cash | 43.45M | 32.41M | 12.70M | 7.67M | 22.80M |
| Total current liabilities | 10.95M | 6.14M | 16.45M | 14.73M | 5.95M |
| Current deferred revenue | - | - | - | - | 0.17M |
| Net debt | -42.52M | -31.37M | -1.67M | 8.20M | -6.55M |
| Short term debt | 0.10M | 0.10M | 10.19M | 8.03M | 1.04M |
| Short long term debt | - | - | 10.15M | 7.85M | 0.62M |
| Short long term debt total | 0.94M | 1.04M | 11.03M | 15.87M | 16.25M |
| Other stockholder equity | 639.14M | 599.88M | 515.03M | 451.61M | 432.83M |
| Property plant equipment | - | - | - | 1.42M | 1.97M |
| Total current assets | 119.53M | 73.76M | 37.16M | 16.16M | 31.15M |
| Net tangible assets | - | - | - | -5.86M | 11.95M |
| Short term investments | 47.58M | 20.82M | 19.81M | - | - |
| Net receivables | 11.74M | 11.06M | 0.39M | 0.37M | 0.04M |
| Long term debt | - | - | - | 7.84M | 15.01M |
| Inventory | 10.25M | 6.93M | 3.32M | 2.00M | 1.41M |
| Accounts payable | 2.66M | 0.96M | 1.01M | 2.02M | 0.64M |
| Accumulated other comprehensive income | 0.57M | 0.08M | 0.14M | -0.08M | 0.02M |
| Common stock total equity | - | - | - | 0.10M | - |
| Retained earnings total equity | - | - | - | -457.48M | - |
| Non currrent assets other | - | - | -0.00M | 0.28M | - |
| Non current assets total | 4.10M | 2.83M | 1.45M | 1.71M | 1.97M |
| Capital lease obligations | 0.94M | 1.04M | 0.04M | 0.19M | 0.62M |
| Long term debt total | - | - | - | 7.84M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -25.04M | -0.98M | -0.04M | -0.21M | -0.14M |
| Change to liabilities | - | - | - | 2.42M | -3.56M |
| Total cashflows from investing activities | -26.59M | -0.98M | -19.71M | -0.21M | -0.14M |
| Net borrowings | 0.00M | -10.61M | -6.31M | -0.71M | 14.44M |
| Total cash from financing activities | 15.05M | 39.41M | 51.78M | 10.14M | 20.82M |
| Change to operating activities | - | - | - | 1.40M | -1.66M |
| Net income | 2.70M | -26.39M | -47.68M | -36.51M | -25.65M |
| Change in cash | 11.04M | 19.72M | 0.87M | -15.13M | -1.80M |
| Begin period cash flow | 32.41M | 12.70M | 11.82M | 26.95M | 28.76M |
| End period cash flow | 43.45M | 32.41M | 12.70M | 11.82M | 26.95M |
| Total cash from operating activities | 22.52M | -18.68M | -31.25M | -24.95M | -22.60M |
| Issuance of capital stock | 0.48M | 7.02M | 29.04M | 10.86M | 0.00M |
| Depreciation | 0.35M | 0.23M | 0.13M | 0.13M | 0.15M |
| Dividends paid | - | - | 51.78M | - | - |
| Change to inventory | -3.32M | -3.61M | -1.32M | -0.59M | -0.56M |
| Change to account receivables | -0.85M | -10.65M | 0.12M | -0.32M | 0.01M |
| Sale purchase of stock | -6.00M | 0.25M | 0.12M | 10.86M | - |
| Other cashflows from financing activities | 15.05M | 43.00M | 35.01M | -0.21M | 20.82M |
| Change to netincome | - | - | - | 0.16M | 8.34M |
| Capital expenditures | 1.55M | 0.56M | 0.06M | 0.21M | 0.14M |
| Change receivables | - | - | - | -0.32M | - |
| Cash flows other operating | - | - | - | 8.99M | - |
| Cash and cash equivalents changes | - | - | - | -15.02M | - |
| Change in working capital | -3.07M | -15.52M | -0.91M | 2.11M | -5.76M |
| Stock based compensation | 24.23M | 9.77M | 8.15M | 7.94M | 7.83M |
| Other non cash items | -1.70M | 13.23M | 9.05M | 1.37M | 0.83M |
| Free cash flow | 20.97M | -19.24M | -31.31M | -25.16M | -22.75M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DCTH Delcath Systems Inc |
0.09 0.63% |
14.38 | 152.29 | 25.77 | 4.35 | 3.38 | 3.35 | 282.74 |
| ABT Abbott Laboratories |
-0.58 0.53% |
109.58 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.38 0.38% |
98.91 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
2.71 0.88% |
309.52 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
0.66 1.38% |
48.35 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
566 Queensbury Avenue, Queensbury, NY, United States, 12804
212 489 2100
156
| Name | Title | Year Born |
|---|---|---|
| Mr. Gerard J. Michel MBA, MS | CEO & Director | 1963 |
| Mr. John Purpura M.S. | Chief Operating Officer | 1961 |
| Dr. Johnny John M.D. | Sr. VP Clinical Devel. & Medical Affairs | 1964 |
| Mr. Anthony C. Dias | VP of Fin. | 1967 |
| Mr. David Hoffman | Gen. Counsel, Corp. Sec. & Chief Compliance Officer | NA |
| Mr. Robin Wagge | Sr. VP of Rubenstein Associates | NA |
| Mr. Kevin Muir | VP of Commercial Operations | NA |
| Dr. Johnny John M.D. | Senior Vice President of Clinical Operations & Medical Affairs | 1965 |
| Ms. Sandra Pennell | Senior VP of Finance and Principal Financial & Accounting Officer | 1979 |
| Dr. Martha S. Rook Ph.D. | Chief Operating Officer | 1972 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.17%
Communication Services
+0.18%
Consumer Cyclical
+0.51%
Consumer Defensive
+0.42%
Energy
-1.23%
Financial Services
+0.48%
Financials
+0.41%
Healthcare
+0.23%
Industrials
+0.31%
Real Estate
+0.26%
Technology
+0.11%
Utilities
+0.05%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...